Professor Michael Schneider
Chair in Cardiology
Faculty of Medicine, National Heart & Lung Institute
Professor Michael Schneider's inventions
Two distinct late stage preclinical lead series of highly specific inhibitors of MAP4K4
A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity Further information on this technology
Sign up for updates
Sign up for monthly technology alerts via email, and find other ways to connect with us.